Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CDC25A | P30304 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL14764881 | 0.98 | MEN1 (0.46) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| SCHEMBL7777410 | 0.79 | MEN1 (0.45) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| SCHEMBL9685830 | 0.79 | PTPN1 (0.52) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| SCHEMBL5810776 | 0.78 | PARK7 (0.58) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| SCHEMBL20375471 | 0.77 | MEN1 (0.48) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| Deoxylapachol SCHEMBL2682330 | 0.77 | MEN1 (0.54) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| SCHEMBL11218822 | 0.77 | MAPT (0.54) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL4784119 | 0.75 | PTPN1 (0.38) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| SCHEMBL7912021 | 0.75 | PTPN1 (0.52) | MEN1KMT2AL3MBTL1NSD2PTPN1 | |
| SCHEMBL3275939 | 0.75 | PTPN1 (0.52) | MEN1KMT2AL3MBTL1NSD2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0065513-B1 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-09-18 | — | — | EP | claimed |
| EP-0065513-A4 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1983-03-29 | — | — | EP | claimed |
| EP-0065513-A1 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1982-12-01 | — | — | EP | claimed |
| WO-1982001821-A1 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF | KOVACS ANDRAS | 1982-06-10 | — | — | WO | claimed |
| CN-109310604-A | Use of specific compounds for modifying, reducing or eliminating off-flavours | 西姆莱斯有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2018-02-22 | — | — | US | disclosed |
| US-9890106-B2 | Anti-cancer lead molecule | KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY (SA) | 2018-02-13 | — | — | US | disclosed |
| EP-3261628-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | King Abdullah University Of Science And Technology (SA) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135633-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY (SA) | 2016-09-01 | — | — | WO | disclosed |
| EP-2844237-A1 | ANTI-CANCER LEAD MOLECULE | King Abdullah University Of Science And Technology (SA) | 2015-03-11 | — | — | EP | disclosed |
| US-20140107196-A1 | ANTI-CANCER LEAD MOLECULE | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2014-04-17 | — | — | US | disclosed |
| WO-2013164683-A1 | ANTI-CANCER LEAD MOLECULE | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2013-11-07 | — | — | WO | disclosed |
| EP-0065513-B1 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-09-18 | — | — | EP | disclosed |
| US-4507241-A | Method for the hydrocarbylation of naphthoquinone derivatives | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-03-26 | — | — | US | disclosed |
| EP-0065513-A4 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1983-03-29 | — | — | EP | disclosed |
| EP-0065513-A1 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1982-12-01 | — | — | EP | disclosed |
| WO-1982001821-A1 | ANTIMYCOTIC SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF | KOVACS ANDRAS | 1982-06-10 | — | — | WO | disclosed |
| US-4110473-A | MITICIDAL ETHERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-T962009-I4 | Reduction of 2-acyl-1-naphthols to 2-alkyl-1-naphthols | Fugitt, Robert Benson (US) | 1977-09-06 | — | — | US | disclosed |
| US-3953482-A | HYDROGEN CHLORIDE CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107196-A1 | ANTI-CANCER LEAD MOLECULE | ACAT2, BRCA1, ALPG | MEN1 4585/4885KMT2A 1124/4885L3MBTL1 29/4885 |
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | CETP, LCAT, MTTP | MEN1 3274/4885KMT2A 890/4885L3MBTL1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.